

Revision date: 29-Dec-2014 Version: 3.2 Page 1 of 10

# 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

**Product Identifier** 

Material Name: Moxidectin Oral Gel

**QUEST® Trade Name:** 

QUEST® 2% Equine Oral Gel Synonyms:

**Chemical Family:** Macrocyclic lactone

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Veterinary product used as anti-worm agent (anthelmintic)

Restrictions on Use: Not for human use

**Details of the Supplier of the Safety Data Sheet** 

Zoetis Belgium S.A. Zoetis Inc. 100 Campus Drive, P.O. Box 651 Mercuriusstraat 20 Florham Park, New Jersey 07932 (USA) 1930 Zaventem **Belgium** 

Rocky Mountain Poison Control Center Phone: 1-866-531-8896

Product Support/Technical Services Phone: 1-800-366-5288

**Emergency telephone number: Emergency telephone number:** 

CHEMTREC (24 hours): 1-800-424-9300 International CHEMTREC (24 hours): +1-703-527-3887

VMIPSrecords@zoetis.com **Contact E-Mail:** 

# 2. HAZARDS IDENTIFICATION

Appearance: Clear gel

Classification of the Substance or Mixture

**GHS - Classification** 

Acute aquatic toxicity: Category 1 Chronic aquatic toxicity: Category 1

**EU Classification:** 

EU Indication of danger: Dangerous for the Environment

EU Symbol:

EU Risk Phrases:

R50/53 - Very toxic to aquatic organisms, may cause long-term adverse effects in the aquatic

environment.

**Label Elements** 

Signal Word: Warning

**Hazard Statements:** H410 - Very toxic to aquatic life with long lasting effects

**Precautionary Statements:** P273 - Avoid release to the environment

P391 - Collect spillage

P501 - Dispose of contents/container in accordance with all local and national regulations

Material Name: Moxidectin Oral Gel

Revision date: 29-Dec-2014

Page 2 of 10

Version: 3.2



Other Hazards

Short Term: May be harmful if swallowed. May cause eye irritation. May cause slight skin irritation. (based

on components).

Known Clinical Effects: Adverse effects associated with therapeutic use include clumsy motion of limbs/trunk (ataxia),

drowsiness, depression, and salivation

**Australian Hazard Classification** 

(NOHSC):

Non-Hazardous Substance. Non-Dangerous Goods.

**Note:** This document has been prepared in accordance with standards for workplace safety, which

requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases.

Your needs may vary depending upon the potential for exposure in your workplace.

# 3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Benzyl Alcohol	100-51-6	202-859-9	Xn; R20/22	Acute Tox.4 (H302) Acute Tox.4 (H332)	<4
Moxidectin	113507-06-5	Not Listed	T;R25 Xi;R36 N;R50/53	Acute Tox.3 (H301) Eye Irrit. 2A (H319) Skin Irrit 3 (H316) Aquatic Acute 1 (H400) Aquatic Chronic 1 (H410)	2

Ingredient	CAS Number	EU	EU Classification	GHS	%
_		EINECS/ELINCS		Classification	
		List			
Disodium EDTA (dihydrate)	6381-92-6	Not Listed	Not Listed	Not Listed	*
Water for injection	7732-18-5	231-791-2	Not Listed	Not Listed	*
Simethicone	8050-81-5	Not Listed	Not Listed	Not Listed	*
Sodium phosphate, dibasic	7558-79-4	231-448-7	Not Listed	Not Listed	*
Sodium dihydrogen phosphate dihydrate	13472-35-0	Not Listed	Not Listed	Not Listed	*
Poloxamer 407	9003-11-6	Not Listed	Not Listed	Not Listed	*
2% polysorbate 80	Proprietary	Not Listed	Not Listed	Not Listed	*

Additional Information: \* Proprietar

Ingredient(s) indicated as hazardous have been assessed under standards for workplace

safety.

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

\_\_\_\_\_

Material Name: Moxidectin Oral Gel

Revision date: 29-Dec-2014

Page 3 of 10

Version: 3.2

# 4. FIRST AID MEASURES

**Description of First Aid Measures** 

**Eye Contact:** Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention

immediately.

**Skin Contact:** Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek

medical attention.

**Ingestion:** Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

**Inhalation:** Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of For information on potential signs and symptoms of exposure, See Section 2 - Hazards

**Exposure:** Identification and/or Section 11 - Toxicological Information.

Medical Conditions None known

Aggravated by Exposure:

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

## 5. FIRE-FIGHTING MEASURES

**Extinguishing Media:** Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Formation of toxic

Products:

Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

## 6. ACCIDENTAL RELEASE MEASURES

### Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

### **Environmental Precautions**

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

#### Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill

**Collecting:** area thoroughly.

**Additional Consideration for** 

Large Spills:

Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

## 7. HANDLING AND STORAGE

### **Precautions for Safe Handling**

\_\_\_\_\_

PZ01577

Material Name: Moxidectin Oral Gel
Revision date: 29-Dec-2014
Page 4 of 10
Version: 3.2

## 7. HANDLING AND STORAGE

When handling, use appropriate personal protective equipment (see Section 8). Use with adequate ventilation. Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. Wash hands and any exposed skin after removal of PPE. Refer to Section 12 - Ecological Information, for information on potential effects on the environment. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

**Storage Conditions:** Store as directed by product packaging.

Specific end use(s): No data available

# 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

**Control Parameters** 

Refer to available public information for specific member state Occupational Exposure Limits.

**Benzyl Alcohol** 

Bulgaria OEL - TWA 5.0 mg/m³
Czech Republic OEL - TWA 40 mg/m³
Finland OEL - TWA 10 ppm
45 mg/m³
Latvia OEL - TWA 5 mg/m³
Lithuania OEL - TWA 5 mg/m³
Poland OEL - TWA 240 mg/m³

Moxidectin

**Zoetis OEL TWA 8-hr** 70 μg/m<sup>3</sup>

**Exposure Controls** 

**Engineering Controls:** Engineering controls should be used as the primary means to control exposures. General

room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne

contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment:

Refer to applicable national standards and regulations in the selection and use of personal

protective equipment (PPE).

**Hands:** Impervious gloves are recommended if skin contact with drug product is possible and for bulk

processing operations.

**Eyes:** Wear safety glasses or goggles if eye contact is possible.

**Skin:** Impervious protective clothing is recommended if skin contact with drug product is possible and

for bulk processing operations.

Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate

respirator with a protection factor sufficient to control exposures to below the OEL.

## 9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Gel Color: Clear

Odor: No data available. Odor Threshold: No data available.

Molecular Formula: Mixture Molecular Weight: Mixture

Solvent Solubility:
Water Solubility:
PH:
No data available
No data available
No data available.
No data available.
No data available

Material Name: Moxidectin Oral Gel

Revision date: 29-Dec-2014

Page 5 of 10

Version: 3.2

# 9. PHYSICAL AND CHEMICAL PROPERTIES

Boiling Point (°C): No data available. Partition Coefficient: (Method, pH, Endpoint, Value)

No data available Moxidectin

Predicted 7 Log D 8.74

**Decomposition Temperature (°C):** No data available.

Evaporation Rate (Gram/s):

Vapor Pressure (kPa):

Vapor Density (g/ml):

Relative Density:

Viscosity:

No data available

No data available

No data available

No data available

Flammablity:

Autoignition Temperature (Solid) (°C):No data availableFlammability (Solids):No data availableFlash Point (Liquid) (°C):No data availableUpper Explosive Limits (Liquid) (% by Vol.):No data availableLower Explosive Limits (Liquid) (% by Vol.):No data available

# 10. STABILITY AND REACTIVITY

Reactivity: No data available

Chemical Stability: Stable under normal conditions of use.

**Possibility of Hazardous Reactions** 

Oxidizing Properties: Non-oxidizing

**Conditions to Avoid:** Fine particles (such as dust and mists) may fuel fires/explosions. **Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers

Hazardous Decomposition No data available

**Products:** 

# 11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

**General Information:** Toxicological properties of the formulation have not been investigated. The information in this

section describes the potential hazards of the individual ingredients and the formulation.

Routes of exposure: eye contact, skin contact

Acute Toxicity: (Species, Route, End Point, Dose)

Moxidectin

Rat Oral LD50 106 mg/kg Rat Dermal LD50 > 2000mg/kg

2% polysorbate 80

Rat Intravenous LD 50 1790 mg/kg

Mouse Oral LD 50 25g/kg

**Benzyl Alcohol** 

Rat Oral LD50 1230 mg/kg Rat Para-periosteal LD50 53mg/kg Rat Inhalation LC50 >4.178mg/L

Material Name: Moxidectin Oral Gel
Revision date: 29-Dec-2014
Page 6 of 10
Version: 3.2

## 11. TOXICOLOGICAL INFORMATION

**Acute Toxicity Comments:** 

A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable

at the highest dose used in the test.

## Irritation / Sensitization: (Study Type, Species, Severity)

#### Moxidectin

Eye Irritation Rabbit Moderate Skin Irritation Rabbit Mild

Skin Sensitization - Beuhler Guinea Pig Negative

#### **Benzyl Alcohol**

Eye Irritation Rabbit Severe Skin Irritation Rabbit Minimal Skin Irritation Guinea Pig Moderate

### Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

#### Moxidectin

28 Day(s) Mouse Oral 75 mg/kg/day NOEL Central nervous system 28 Day(s) Oral 100 mg/kg/day LOEL Central Nervous System Rat 13 Week(s) Rat Oral 50 mg/kg/day NOEL Central Nervous System 90 Day(s) Dog Oral 10 mg/kg/day NOEL Central Nervous System

#### Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

### Moxidectin

Embryo / Fetal Development Rabbit Oral 1 mg/kg bw/day NOEL Maternal toxicity, Not teratogenic

Embryo / Fetal Development Rat Oral 5 mg/kg/day NOEL Negative

Embryo / Fetal Development Rat Oral 5 mg/kg bw/day NOEL Not Teratogenic, Embryotoxicity, Maternal Toxicity

#### Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

### Moxidectin

In Vitro Bacterial Mutagenicity (Ames) Salmonella, E. coli Negative

In Vitro HGPRT Forward Gene Mutation Assay Chinese Hamster Ovary (CHO) cells Negative

In Vivo Cytogenetics Rat Bone Marrow Negative

In Vivo Unscheduled DNA Synthesis Rat Hepatocyte Negative

## Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

# Moxidectin

2 Year(s) Mouse Oral 30 mg/kg/day NOEL Not carcinogenic2 Year(s) Rat Oral 100 mg/kg/day NOEL Not carcinogenic

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

Product Level Toxicity Data
Acute Toxicity Estimate (ATE),
oral

4545 mg/kg

Material Name: Moxidectin Oral Gel

Revision date: 29-Dec-2014

Page 7 of 10

Version: 3.2

## 12. ECOLOGICAL INFORMATION

Environmental Overview: Very toxic to aquatic life with long lasting effects. Releases to the environment should be

avoided.

**Toxicity:** 

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Moxidectin

Lepomis macrochirus (Bluegill Sunfish) LC50 96 Hours 0.62 ppb Oncorhynchus mykiss (Rainbow Trout) LC50 96 Hours 0.16 ppb

Daphnia Magna (Water Flea) EC50 48 Hours 30 ppt

Selenastrum capricornutum (Green Alga) EC50 72 Hours > 87 ppb

Benzyl Alcohol

Pimephales promelas (Fathead Minnow) EPA LC50 96 Hours 460 mg/L

Daphnia magna (Water Flea) OECD EC50 48 Hours 230 mg/L

Pseudokirchneriella subcapitata (Green Alga) OECD EC50 72 Hours 500 mg/L

Aquatic Toxicity Comments: A greater than symbol (>) indicates that aquatic toxicity was not observed at the maximum

dose tested.

**Benzyl Alcohol** 

Daphnia magna (Water Flea) OECD 21 Day(s) EC50 66 mg/L Reproduction

Persistence and Degradability:

**Benzyl Alcohol** 

OECD Activated sludge Ready 92% After 14 Day(s) Ready

**Bio-accumulative Potential:** 

Moxidectin

Predicted 7 Log D 8.74

Mobility in Soil: No data available

## 13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State

specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

# 14. TRANSPORT INFORMATION

\_\_\_\_\_

Material Name: Moxidectin Oral Gel

Revision date: 29-Dec-2014

Page 8 of 10

Version: 3.2

As of January 1, 2015, materials offered for transport that are classified for transportation only as Marine Pollutants and which are packaged in single or combination packagings containing a net quantity per single or inner packaging of 5 Liters or less for liquids or having a net mass per single or inner packaging of 5 kilograms or less for solids are NOT subject to ICAO/IATA, IMDG, or ADR transport regulations provided the general packaging requirements of those regulations are met. Refer to ICAO/IATA A197, IMDG 2.10.2.7, ADR SP 375.

UN number: UN 3082

**UN proper shipping name:** Environmentally hazardous substances, liquid, n.o.s. (moxidectin)

Transport hazard class(es): 9
Packing group: |||

Environmental Hazard(s): Marine Pollutant

Please refer to the applicable dangerous goods regulations for additional information. Transport according to the requirements of the appropriate regulatory body.

DOT / ANTT: Not regulated for transportation

U.S. DOT Reportable Quantity (RQ), 49 CFR 172.101 Appendix A:

Sodium phosphate, dibasic

CERCLA/SARA Hazardous Substances 5000 lb and their Reportable Quantities: 2270 kg

# 15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications

WHMIS hazard class:

Non-controlled

This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

**Disodium EDTA (dihydrate)** 

CERCLA/SARA 313 Emission reporting

California Proposition 65

Australia (AICS):

Present

EU EINECS/ELINCS List

Not Listed

Not Listed

Water for injection

CERCLA/SARA 313 Emission reporting

Not Listed
California Proposition 65

Not Listed

Page 9 of 10

Material Name: Moxidectin Oral Gel

Revision date: 29-Dec-2014 Version: 3.2

15. REGU	LATORY	INFOR	MATION

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

REACH - Annex IV - Exemptions from the

Present

obligations of Register:

EU EINECS/ELINCS List 231-791-2

**Simethicone** 

CERCLA/SARA 313 Emission reporting

California Proposition 65

Australia (AICS):

Present

EU EINECS/ELINCS List

Not Listed

Not Listed

Sodium phosphate, dibasic

CERCLA/SARA 313 Emission reporting

CERCLA/SARA Hazardous Substances

and their Reportable Quantities:

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Present

EU EINECS/ELINCS List

Not Listed

Present

2270 kg

Not Listed

Present

231-448-7

Sodium dihydrogen phosphate dihydrate

CERCLA/SARA 313 Emission reporting

California Proposition 65

Australia (AICS):

Present

EU EINECS/ELINCS List

Not Listed

Not Listed

Poloxamer 407

CERCLA/SARA 313 Emission reporting

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS/ELINCS List

Not Listed

Not Listed

Not Listed

Benzyl Alcohol

CERCLA/SARA 313 Emission reporting

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Present

EU EINECS/ELINCS List

Not Listed

Not Eisted

Not

2% polysorbate 80

CERCLA/SARA 313 Emission reporting

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Present

EU EINECS/ELINCS List

Not Listed

Moxidectin

CERCLA/SARA 313 Emission reporting

Not Listed
California Proposition 65

Not Listed

PZ01577

Material Name: Moxidectin Oral Gel Page 10 of 10
Revision date: 29-Dec-2014 Version: 3.2

\_\_\_\_\_

# 15. REGULATORY INFORMATION

Standard for the Uniform Scheduling Schedule 4 for Drugs and Poisons: Schedule 5

Schedule 6 Schedule 7

EU EINECS/ELINCS List Not Listed

## **16. OTHER INFORMATION**

### Text of R phrases and GHS Classification abbreviations mentioned in Section 3

Acute toxicity, oral-Cat.3; H301 - Toxic if swallowed Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed Acute toxicity, inhalation-Cat.4; H332 - Harmful if inhaled

Hazardous to the aquatic environment, acute toxicity-Cat.1; H400 - Very toxic to aquatic life

Hazardous to the aquatic environment, chronic toxicity-Cat.1; H410 - Very toxic to aquatic life with long lasting effects

Serious eye damage/eye irritation-Cat.2A; H319 - Causes serious eye irritation

Skin corrosion/irritation-Cat.3; H316 - Causes mild skin irritation

N - Dangerous for the environment

T - Toxic

Xn - Harmful

Xi - Irritant

R25 - Toxic if swallowed. R36 - Irritating to eyes.

R20/22 - Harmful by inhalation and if swallowed.

R50/53 - Very toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment.

**Data Sources:** The data contained in this MSDS may have been gathered from confidential internal sources,

raw material suppliers, or from the published literature.

**Reasons for Revision:** Updated Section 14 - Transport Information.

Prepared by: Toxicology and Hazard Communication

Zoetis Global Risk Management

Zoetis Inc. believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

**End of Safety Data Sheet** 

\_\_\_\_\_